Main Uses of Lefra

Lefra is a medication primarily utilized in the management of chronic inflammatory conditions affecting the joints. It belongs to a class of drugs known as disease-modifying antirheumatic drugs (DMARDs). Unlike medications that only address immediate symptoms like pain or swelling, this therapy is designed to influence the underlying disease process.

Rheumatoid Arthritis

The primary application of Lefra is for the treatment of active rheumatoid arthritis in adults. In this condition, the immune system mistakenly attacks the synovium—the lining of the membranes that surround the joints. Lefra works by modulating the immune response, specifically by inhibiting the overproduction of certain immune cells that contribute to inflammation.

Psoriatic Arthritis

Lefra is also used to treat active psoriatic arthritis. This condition occurs in some individuals who have psoriasis, a skin disease characterized by red, scaly patches. Psoriatic arthritis involves joint inflammation similar to rheumatoid arthritis, often affecting the fingers, toes, or spine. The medication helps manage the joint-related symptoms associated with this systemic inflammatory disorder.

Benefits and Clinical Goals

The use of Lefra is centered on long-term joint health and improving the daily quality of life for patients with chronic arthritis.

Reduction of Signs and Symptoms

A major goal of treatment is the significant reduction of clinical symptoms. This includes:

• Decreasing joint pain and tenderness.
• Reducing visible swelling and inflammation in affected joints.
• Improving morning stiffness, allowing for better mobility early in the day.

Inhibition of Structural Damage

One of the most critical benefits of Lefra is its potential to slow down the progression of the disease. By controlling inflammation at its source, the medication helps to:

• Inhibit the rate of structural damage to the joints.
• Reduce the progression of joint erosions and space narrowing as seen on X-rays.
• Preserve joint integrity over time.

Improvement in Physical Function

By managing pain and protecting joint structure, Lefra aims to restore or maintain a patient’s ability to perform daily activities. This improvement in physical function often results in greater independence and the ability to participate in work, social, and recreational activities that might otherwise be limited by arthritic symptoms.

Regulatory References

1. EMA therapeutic overview

Official Eligibility Rules for Lefra (Leflunomide)

Lefra is officially approved only for adult patients (aged 18 and older) with active Rheumatoid Arthritis or active Psoriatic Arthritis. Regulatory bodies define strict rules for its use based on age, reproductive status, and specific health conditions.

---

Population Status	Official Regulatory Classification
Contraindicated Populations	Pregnant women, breastfeeding women, and women of childbearing potential not using reliable contraception.
Organ/System Restrictions	Patients with severe hepatic impairment (liver function impairment), pre-existing acute or chronic liver disease, or baseline ALT > 2 imes ULN are prohibited from using Lefra.
Comorbidity Prohibitions	Contraindicated in patients with severe immunodeficiency states (e.g., AIDS), significantly impaired bone marrow function, or severe hypoproteinaemia. The medicine must not be started in the presence of serious active infections.
Age Restriction	Not recommended for patients under 18 years as safety and effectiveness have not been established in the pediatric population.
Conditional Use	Caution is required for patients with moderate to severe renal insufficiency (kidney impairment) and those with a history of interstitial lung disease.

---

Regulatory documentation establishes an adult-only eligibility rule and strictly defines who cannot use the medicine by listing multiple absolute exclusions. These constraints ensure that the medicine is reserved for the intended adult population who do not present with severe risks to reproductive health, liver function, or immune system integrity, as outlined in official labeling.

Interactions with other medicines and products

The interaction profile of Lefra (Leflunomide) is defined by the activity of its major active metabolite, A771726, which is a documented modulator of drug-processing systems. Co-administration with other medicines may lead to altered exposure of either agent or increased risk of specific toxicities.

Documented Pharmacokinetic and Transporter Interactions

The active metabolite A771726 is an inhibitor of the CYP2C9 enzyme, which can increase the plasma concentrations of co-administered drugs metabolized by this pathway, such as Warfarin and Phenytoin. Additionally, A771726 inhibits the drug transporters BCRP and OATP1B1/B3. This transporter inhibition has been documented to significantly increase the systemic exposure (AUC and Cmax) of substrates like Rosuvastatin.

Pharmacodynamic and Elimination Interactions

The combination of Leflunomide with alcohol or other known hepatotoxic agents may result in an increased risk of severe liver injury due to officially documented additive toxicity. Co-administration with Teriflunomide is not recommended due to the potential for excessive systemic exposure to the active metabolite. For accelerated elimination, binding agents like Cholestyramine or Activated Charcoal are utilized to rapidly decrease the active metabolite’s plasma concentration by interrupting its enterohepatic circulation.

Population and Restriction Notes

Use of Lefra is contraindicated in patients with severe hepatic impairment. Vaccination with live attenuated vaccines is not recommended during treatment.

How Lefra Works: The Pharmacodynamic Mechanism

Targeting Cell Growth via Enzyme Inhibition

Lefra's activity begins with its conversion to the active metabolite, A771726 (Teriflunomide), which acts as a potent inhibitor of the mitochondrial enzyme Dihydroorotate Dehydrogenase (DHODH). This targeted action halts the de novo pyrimidine synthesis pathway, disrupting the supply of necessary nucleotide building blocks (DNA and RNA) required for cell division. This physiological effect results in the cytostasis (growth arrest) of rapidly multiplying immune cells, specifically hyperactive T-lymphocytes, which are highly dependent on this pathway for their expansion.

Selective Immune Cell Modulation

The resulting pyrimidine depletion preferentially affects overactive T-cells, forcing them into G1 phase cell cycle arrest and limiting their clonal expansion, an effect associated with selective inhibition of lymphocyte proliferation. Furthermore, the active metabolite modulates key signaling proteins, such as specific Protein Tyrosine Kinases (PTKs), which contribute to the suppression of T-cell activation and differentiation. This dual mechanism results in a systemic dampening of the cellular immune system activity and is associated with a modulation and reduced release of pro-inflammatory mediators (e.g., TNF-α and IL-6).

How to Use Lefra

Lefra (Leflunomide) is administered as an oral tablet and is used as part of a long-term daily regimen for the management of active rheumatoid and psoriatic arthritis. The administration procedure is standardized to ensure consistent systemic use.

---

Official Administration Guidelines

Instruction	Detail
Route of Administration	Oral administration
Approved Strengths	10 mg, 20 mg, and 100 mg tablets
Maximum Daily Dose	20 mg once daily

---

Standard Dosing Regimens and Schedule

Lefra therapy typically begins with an initial phase followed by a consistent maintenance phase, though the starting phase is optional:

• Optional Initial Phase (Loading Dose): For some individuals, treatment may begin with 100 mg once daily for three consecutive days to help the active metabolite reach required levels more quickly. This initial step may be omitted.
• Maintenance Phase: Following the initial phase, or starting directly, the usual maintenance dose is 10 mg or 20 mg taken once daily.

Administration Conditions and Patient Groups

The tablets should be swallowed whole with sufficient liquid. Lefra may be taken with or without food. No initial dose adjustment is required for older adults (over 65 years) or for patients with mild renal impairment.

Research evidence / Overview of Studies for Lefra (Leflunomide)

---

Evidence for use in conditions characterized by fluctuating or episodic manifestations (Rheumatoid Arthritis)

The foundational research for Lefra in Rheumatoid Arthritis (RA) was studied for adults with this condition marked by functional limitations. The evidence base includes multiple large-scale randomized controlled trials (RCTs) exploring short-term symptom changes, primarily observing responses over defined time intervals of six months to two years. These trials were evaluated in comparison to a placebo or to other established treatments like methotrexate (MTX). The research examined measures of outcomes related to joint activity (such as tender and swollen joint counts) and outcomes reflecting daily functioning or activity level.

Evidence for use in conditions involving periods of heightened symptoms (Psoriatic Arthritis)

Research for the use of Lefra in Psoriatic Arthritis (PsA) was evaluated in a pivotal multinational Randomized, Double-Blind, Placebo-Controlled Trial. This research explored outcomes linked to inflammatory or irritative states using specialized criteria to measure joint activity. Studies monitored the extent of both measures of joint activity and the severity of associated skin involvement (psoriasis) over defined time intervals, typically around 24 weeks. The overall evidence base for this specific indication relies primarily on one pivotal trial.

---

Long-term Studies and Durability of Response

Lefra was studied for both short-term activity and long-term effects on the condition. The longest clinical trial extensions and subsequent observational studies describe follow-up durations that track patients for up to two years under controlled conditions and even longer in real-world settings. The studies report how symptoms evolved in the observed populations over these multi-year periods. However, the long-term patterns of response and maintenance of treatment, particularly compared to newer classes of medicines, are not fully established by the controlled trials.

What Is Still Uncertain About Lefra Research

Despite the established evidence base, certainty remains low in several areas that research is exploring. Long-term comparative evidence is lacking in large-scale, long-duration RCTs that directly compare Lefra to many newer treatments. Data regarding outcomes in specific groups, such as those with pre-existing, non-arthritis-related lung conditions, are still emerging, and evidence is limited to small cohort or case reports. Findings describe group patterns, not personal outcomes, and the research does not determine whether an individual will respond similarly.

Common questions about Lefra (FAQ)

Q: What is the main difference between Lefra and other similar medications?

Official regulatory documents indicate that Lefra is a type of Disease-Modifying Antirheumatic Drug (DMARD) that functions as a prodrug. This means the medicine is not active until it is converted by the body into its highly active metabolite. This active form works by inhibiting a specific enzyme called Dihydroorotate Dehydrogenase (DHODH), a key action that limits the growth of certain overactive immune cells.

Q: Are there any specific foods or drinks to avoid while taking Lefra?

Official product information states that the medicine may be taken with or without food. However, there are official warnings about an increased risk of severe liver injury when Lefra is used in combination with alcohol or other known hepatotoxic agents (substances that can harm the liver).

Q: Is Lefra safe to use long-term?

Lefra is designated for long-term daily use in treating chronic conditions. Official warnings indicate that due to the potential for serious adverse effects, such as severe liver injury, official documentation describes a requirement for mandatory, periodic safety monitoring of liver enzymes and blood cell counts.

Q: Does Lefra interact with birth control pills?

Due to the established risk of fetal harm, regulatory documents specify that females of childbearing potential are required to use effective contraception throughout treatment and during the recommended drug elimination procedure after stopping the medicine. The official labeling warns about the risk of fetal harm if contraception fails.

Q: Do the side effects of Lefra go away after a while?

Due to the prolonged way the medicine is processed, its active component has a long half-life, meaning it stays in the body for an extended time (approximately 1 to 4 weeks). Because of this, serious side effects may persist or appear even after the medicine has been stopped. The official label describes the use of a medical procedure known as accelerated elimination (or washout) to shorten the time the active metabolite remains in the body.

Q: How long does Lefra stay in the system after the last dose?

The active substance of Lefra has a prolonged half-life, typically ranging from 1 to 4 weeks. If an accelerated drug elimination procedure (washout) is not utilized, the metabolite may persist in the system for up to two years.

Q: What is the maximum duration of use described for Lefra?

Lefra is officially classified as a long-term daily regimen medicine for chronic diseases. While regulatory documents do not define a hard maximum duration limit, clinical trials evaluating its effectiveness have followed patients for periods of up to two years.

Q: Are there documented cases of allergic reactions to Lefra?

Official information states that hypersensitivity to the active substance is a contraindication. Severe, sometimes life-threatening, allergic reactions (such as Stevens-Johnson syndrome and angioedema) have been reported and are highlighted in the safety documentation.

Q: Does Lefra affect fertility?

The official product label does not contain specific information about whether Lefra affects the ability of men or women to conceive (fertility). However, it is strictly contraindicated (prohibited) due to the serious risk of fetal harm if pregnancy occurs.

Q: Why do official sources list this specific contraindication for Lefra?

Lefra is classified as an immunosuppressive agent because it acts to moderate the activity of the immune system. Contraindications like severe immunodeficiency and significantly impaired bone marrow function are listed because the medicine's mechanism of action could worsen these pre-existing conditions.

Q: What is the purpose of the boxed warning on Lefra?

The FDA includes a Boxed Warning—the most serious type of warning—to call attention to critical safety concerns. This warning highlights the risk of Embryo-Fetal Toxicity (due to the risk of fetal harm) and the potential for Severe Liver Injury, including fatal liver failure.

Q: What is the difference between the immediate-release and extended-release forms of Lefra?

The medicine is supplied as an oral tablet in 10 mg, 20 mg, and 100 mg strengths. Official regulatory documents do not mention or differentiate between immediate-release (IR) and extended-release (ER) formulations for this product.

Q: How long does it usually take to feel the effects of Lefra?

Clinical observations indicate that the therapeutic effect of the medicine is typically observed starting after 4 to 6 weeks of consistent treatment. Continued improvement of symptoms may occur over time as treatment progresses.

Q: Does Lefra interact with common pain relievers like ibuprofen?

Official information indicates that the active metabolite of Lefra is cleared via the liver. Taking it with other medications that can also affect the liver, such as nonsteroidal anti-inflammatory drugs (NSAIDs) like Ibuprofen, may increase the potential risk of liver injury.

Q: Do I need to stop taking Lefra slowly, or can I stop suddenly?

Regulatory documents describe that the medicine is not required to be tapered. However, due to the prolonged amount of time the active substance stays in the body, an accelerated drug elimination procedure (washout) is described in official documentation. This procedure is often utilized before pregnancy or if toxicity occurs.

Q: Is it normal to feel tired when starting Lefra?

Clinical trials have documented asthenia as an adverse event in some patients. Asthenia is a medical term used to describe a physical weakness or lack of energy/tiredness that can occur.

Q: Can taking Lefra cause problems with my vision?

Official safety data reports that adverse events affecting the eyes, including blurred vision, conjunctivitis (pink eye), and cataract, have been observed in clinical trials.

Q: Are there known interactions between Lefra and common cold medicines?

Some common cold medicines contain Acetaminophen, and taking Lefra with these products may increase the risk of liver problems. Official regulatory information specifies caution regarding exceeding the maximum recommended daily dosage of Acetaminophen.

Q: Can Lefra affect the results of lab tests?

Lefra is associated with transient, frequent elevations in serum aminotransferase levels (ALT and AST). These are key markers measured in liver function tests. The product label specifies the requirement for mandatory periodic monitoring using these key markers during treatment.

Official Storage and Disposal Instructions

Leflunomide (Lefra) tablets must be stored according to regulatory requirements to ensure product stability. The official required storage temperature is controlled room temperature, typically 20°C to 25°C (68°F to 77°F), with permitted brief excursions up to 30°C. The medication must be kept in its original container and, if in a bottle, the cap must be kept tightly closed to protect the contents from moisture and direct light.

---

It is a mandatory regulatory requirement to keep all forms of this medicine out of the sight and reach of children.

Disposal of any unused, outdated, or waste material must be conducted in accordance with local requirements. The product should not be released into the environment, and specific local guidelines should be followed for pharmaceutical waste.